LifeScience Clinical & Diagnostic
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from t...
May 14, 2026 | News
Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the prelimina...
May 13, 2026 | News
Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreement...
May 13, 2026 | News
Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhala...
May 11, 2026 | News
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...
May 11, 2026 | News
Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Investigation...
May 11, 2026 | News
PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 ...
May 07, 2026 | News
Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies...
May 07, 2026 | News
New Gibco™ CTS™ DynaXS™ Single Use Bioreactor supports flexible, cGMP-ready cell expansion from process development to clinical productio...
May 05, 2026 | News
EnGeneIC announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGene...
May 05, 2026 | News
Strategic combination unites Cardioline’s global reach and proven cardiac technology with Cardios’s decades of clinical expertise in Holter m...
May 05, 2026 | News
Phase I/II clinical trial interim results, out to 168 days, from the two RV-001 dosing cohorts with advanced Retinitis Pigmentosa are presented at key Ma...
May 04, 2026 | News
Nu-3 represents a novel class of potent, fast-acting, broad-spectrum antimicrobials called Bisphosphocins® Lakewood-Amedex Biotherapeutics Inc., (NASD...
May 04, 2026 | News
SUNRISE-II feasibility trial marks the company's entry into U.S. clinical development, advancingminimally invasive, anesthesia-free treatment approach Son...
May 04, 2026 | News
Most Read
Bio Jobs
News
Editor Picks